• Julie Lemieux, Caroline Diorio, Marc-André Côté, Louise Provencher, Frédéric Barabé, Simon Jacob, Christine St-Pierre, Eric Demers, Rosemarie Tremblay-Lemay, Corinne Nadeau-Larochelle, Annick Michaud, and Christian Laflamme.
• Oncology Axis, CHU of Quebec Research Center, Quebec City, QC, Canada. julie.lemieux@uresp.ulaval.ca
• Anticancer Res. 2013 Jun 1;33(6):2569-76.

BackgroundTrastuzumab has no major side-effects except the potential for cardiac toxicity. The main objective of this study was to evaluate the association between trastuzumab-associated cardiac toxicity and two potential risk factors: alcohol intake and HER2 polymorphisms.Patients And MethodsIn a retrospective cohort study of 237 women with non-metastatic HER2-positive breast cancer treated with trastuzumab, traditional risk factors were assessed by review of medical records, alcohol use by an administered questionnaire to women (n=132), and HER2 polymorphisms (Ile655Val and Ala1170Pro) using TaqMan assays (n=73).ResultsAssociation was observed between alcohol intake (10 drinks and more per week) during the trastuzumab treatment and cardiac toxicity (p=0.04). For polymorphisms, compared to Ile/Ile carriers, HER2 Ile/Val was associated with a higher risk of cardiac toxicity (p=0.02).ConclusionHeavy alcohol use during the course of trastuzumab treatment and the HER2 Ile/Val genotype may constitute risk factors for cardiac toxicity.

44 keywords...

hide…